BrainStorm Cell Therapeutics, Inc. (BCLI.OB) Announces Superior Stem Cell Treatments
Today, BrainStorm Cell Therapeutics Inc. took the opportunity to announce that the company’s therapeutic treatment for neurodegenerative diseases displayed superior results to other current potential stem cell treatments in a recently conducted study. The Israel Medical Association Journal published a scientific paper, authored by Ofer Sadan, Eldad Melamed and Daniel Offen from Tel Aviv University, showing the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s and Huntington diseases. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior in behavior, biochemical and histological indices to that of mesenchymal…